Nurix Therapeutics
NRIX
22.73
+0.13
+0.58%
Nurix Therapeutics
US · NRIX
#2679 by market cap
Listed 2020
22.73
+0.13
+0.58%
Live - 5344 symbols - heartbeat 559s ago
· 2026-10-08 06:18
Pre-market
22.44
-1.30%
After-hours
22.73
0.00%
- Market cap
- 2.36B
- P/E (TTM)i
- -6.57
- P/Bi
- 5.86
- EPSi
- -3.05
- Div yieldi
- 0.00%
- 52W posi
- 71%
Reader sentiment
Are you bullish or bearish on NRIX?
Anonymous reader poll. Unscientific, not investment advice.
About Nurix Therapeutics
Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in the business of discovering, developing, and commercializing innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in Brisbane, CA.
- Founded
- 2009
- CEO
- Dr. Arthur T. Sands, M.D.,PhD
- Employees
- 317
- Headquarters
- Brisbane, California, United States of America
- Fiscal year end
- 11-30
- Website
- nurixtx.com
Company profile
- Exchange
- US
- Symbol
- NRIX
- Market-cap rank
- #2679
- Listing date
- 2020-07-24
- Market cap
- 2.36B
- Float cap
- 1.68B
- Shares out
- 103.78M
- Float shares
- 74.11M
Sectors & themes
Quote time 2026-10-08 06:18:54 · For reference only, not investment advice and not tailored to your situation.